每经AI快讯，浙江医药（SH 600216，收盘价：14.03元）11月26日晚间发布公告称，公司第十届九次董 事会会议于2025年11月26日以通讯表决方式召开。会议审议了《关于筹划控股子公司分拆上市的议案》 等文件。 （记者 张明双） 截至发稿，浙江医药市值为135亿元。 每经头条（nbdtoutiao）——国开行辟谣的"人民资产"是什么？记者实探：号称投资600元80天赚8万 元！一位投资人的女儿：劝不住她，警察都拦不住 2025年1至6月份，浙江医药的营业收入构成为：药品占比51.44%，人类营养品占比47.06%，其他占比 0.85%，其他业务占比0.66%。 ...

Core Viewpoint - Zhejiang Medicine announced an incentive plan involving 875 participants, granting up to 10.284 million restricted stocks, representing approximately 1.0694% of the company's total share capital of about 962 million shares [1] Group 1: Incentive Plan Details - The incentive plan will grant restricted stocks at a price of 7.3 yuan per share, with a maximum validity of 36 months from the completion of the stock registration [1] - The stocks are sourced from the company's repurchased A-shares in the secondary market, with no reserved rights set [1] Group 2: Financial Performance - For the first half of 2025, Zhejiang Medicine's revenue composition is as follows: pharmaceuticals account for 51.44%, human nutritional products for 47.06%, and other businesses for 1.51% [1] - As of the report date, Zhejiang Medicine's market capitalization stands at 13.9 billion yuan [1]

Core Viewpoint - Zhejiang Medicine announced a board meeting to discuss the 2025 restricted stock incentive plan, indicating a strategic move to enhance employee motivation and align interests with shareholders [1] Financial Performance - For the first half of 2025, Zhejiang Medicine's revenue composition was as follows: pharmaceuticals accounted for 51.44%, human nutritional products for 47.06%, other products for 0.85%, and other business activities for 0.66% [1] Market Position - As of the report, Zhejiang Medicine's market capitalization stood at 13.9 billion yuan [1]

Core Viewpoint - Zhejiang Medicine announced the completion of a share buyback, acquiring approximately 13.72 million shares, which represents 1.43% of the company's total equity, at an average price of 14.57 CNY per share, totaling around 200 million CNY in funds used [1] Group 1: Share Buyback Details - The company completed the buyback on August 11, 2025, through a centralized bidding method on the Shanghai Stock Exchange [1] - The highest buyback price was 16.09 CNY per share, while the lowest was 13.31 CNY per share [1] - The total number of shares repurchased was approximately 13.72 million [1] Group 2: Revenue Composition - For the year 2024, the revenue composition of Zhejiang Medicine is as follows: human nutritional products accounted for 50.1%, pharmaceuticals for 48.85%, and other businesses for 1.05% [1] - The contribution from other businesses includes 0.64% from other categories and 0.41% from additional services [1] Group 3: Market Capitalization - As of the report, Zhejiang Medicine's market capitalization stands at 15 billion CNY [1]